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Abstract: Efforts to scale-up HIV care and treatment have been successful at initiating large 
numbers of patients onto antiretroviral therapy (ART), although persistent challenges remain 
to optimizing scale-up effectiveness in both resource-rich and resource-limited settings. 
Among the most important are very high rates of ART initiation in the advanced stages of 
HIV disease, which in turn drive morbidity, mortality, and onward transmission of HIV. 
With a focus on sub-Saharan Africa, this review article presents a conceptual framework 
for a broader discussion of the persistent problem of late ART initiation, including a need 
for more focus on the upstream precursors (late HIV diagnosis and late enrollment into 
HIV care) and their determinants. Without additional research and identification of multi-
level interventions that successfully promote earlier initiation of ART, the problem of late 
ART initiation will persist, significantly undermining the long-term impact of HIV care 
scale-up on reducing mortality and controlling the HIV epidemic.
Key words: Late ART initiation, sub-Saharan Africa, scale-up, conceptual framework, 
retention.
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An estimated 34 million people are infected with HIV worldwide, the majority in developing countries.1 Efforts to scale-up access to HIV care and treatment have 
been successful at initiating large numbers of patients on antiretroviral therapy (ART). 
Sub-Saharan Africa is the most affected region, constituting 69% of people living with 
HIV/AIDS and 70% of HIV/AIDS deaths worldwide.1 The estimated number of people 
on ART in the region increased from 100,000 people in 2003 to 8 million by the end 
of 2011, reaching an estimated 44% of those in need.1 Despite these successes, there 
remain persistent challenges to optimizing the effectiveness of HIV care and treatment 
scale-up in the region. Among the most important of these are very high rates of late 
ART initiation (i.e., in the advanced stages of HIV disease) 2,3 which in turn drive high 
rates of mortality soon after initiation of ART (early mortality).4,5 A three-to-four fold 
difference in mortality rates is apparent in the first year after ART initiation in resource-
limited as compared with resource-rich settings.6 There are also very high mortality 
rates prior to ART initiation among people already diagnosed and enrolled in care.2 
Late ART initiation is also associated with a longer infectious period, and earlier ART 
initiation substantially reduces onward HIV transmission.7 
The aim of this review is to draw on relevant literature from around the world to 
examine and discuss the magnitude of the late ART initiation problem in sub-Saharan 
Africa, including precursors of late ART initiation (late HIV diagnosis and late enroll-
ment into HIV care). We discuss the pathways to late ART initiation, which may in turn 
be associated with different determinants and interventions, and present a conceptual 
framework to help guide future discussions and inform studies aimed at identifying 
determinants and interventions that ultimately increase the effectiveness of HIV care 
and treatment scale-up.
international treatment guidelines and definition of late art initiation. With few 
exceptions, national guidelines in the sub-Saharan African region during 2004–2009 
specified ART eligibility for patients with CD41 counts ,200 cells/μL.8 In 2009, the 
World Health Organization (WHO) revised its guidelines for ART eligibility to start 
patients on ART earlier: CD4 count #350 cells/μL (irrespective of WHO stage) and 
WHO stage 3 or 4 (irrespective of CD4 count).9 Subsequently, many sub-Saharan 
African countries have updated their HIV national guidelines to reflect these new 
recommendations. National guidelines, however, still vary greatly and while they are 
an important reference point, most patients in sub-Saharan Africa have historically 
initiated ART at levels well below international and national guidelines that were in 
effect at the time of ART initiation (e.g., median of 80–212 cells/µL).10–32 
For the purposes of this review, we broadly define late ART initiation as initiating 
ART in the advanced stages of HIV infection, irrespective of the reason. We do not 
put forth an operational definition, given the relative variability across countries and 
contexts. Rather, we frame our discussion of what constitutes late as being on the low 
end (e.g., lowest 25% or 10%) of the distribution of CD4 count or clinical stage at ART 
initiation in a given setting. However, as a reference point, operational definitions used 
in epidemiologic studies include WHO stage 433–35 or CD4 #200 cells/µL17,33,35–40 to define 
late and CD4 ,50 cells/µL to define very late.37–40 In the past years, some attempts have 
been made to create consensus on these definitions,41–43 but given that international 
guidelines tend to evolve and CD4 count at ART initiation is not universally available 
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among HIV patients in sub-Saharan Africa, it is advisable to use both CD4 and clinical 
stage information when operationally defining late ART initiation. 
Methods
We conducted a literature review to identify the extent to which studies had been pub-
lished on the magnitude of the late ART initiation problem, its precursors (late HIV 
diagnosis and late enrollment into HIV care) and their determinants in sub-Saharan 
Africa. English-language, peer-reviewed publications from 2005 to 2011 were searched 
in PubMed, using the terms (late OR delay) AND antiretroviral AND initiation. Addi-
tional articles were identified from references in published papers and abstracts from 
major international AIDS conferences. The PubMed search yielded 148 articles. We 
only included reports of observational ART cohorts in sub-Saharan Africa reporting 
CD41 cell count and/or WHO/CDC clinical staging. We excluded data from controlled 
clinical trials and from special populations, such as female sex workers and intravenous 
drug users, as the findings are likely not generalizable to all people with HIV. Table 1 
presents results from 27 studies from 18 African countries reporting the median CD4 
and/ or clinical staging at HIV diagnosis, enrollment into care, and ART initiation 
among patients enrolled in care and treatment between 1998 and 2009, as well as the 
definition and proportion considered late when available. 
results
The magnitude of the late art initiation problem in sub-Saharan africa. Despite 
more expansive guidelines for ART eligibility, most patients in sub-Saharan Africa 
initiate ART at very low CD4 counts,2,6,10,12,13,19,21,22,27,28,44,45 with substantial variability in 
the CD4 count at ART initiation across sites and settings.8,28 We observed a range of 
median CD4 counts from 87 to 212 cells/µL at ART initiation (Table 1) in our review 
of the published literature in sub-Saharan Africa from 2005 to 2011. Table 1 also notes 
median CD4 count at the key milestones on the pathways towards ART initiation (HIV 
diagnosis and enrollment into care). In an analysis from the ART-LINC collaboration, 
which included 36,715 patients from 17 centers in 12 low-income countries, the median 
CD4 count at ART initiation was 122 cells/μL (IQR 53-194) among the sub-Saharan 
African patients.19,28 Some of the most recent publications on scale-up programs for 
which CD4 and stage information are available suggest that, while the median CD4 
count at ART initiation is increasing, they remain quite low among sub-Saharan Afri-
can ART patients.19,27,28 For example, one recent analysis of 121,504 patients initiating 
ART from 267 clinics in eight sub-Saharan African countries found that the median 
CD4 cell count at ART initiation increased modestly from 115 to 143 cells/µL during 
2004–2008.28 
The very low CD4 counts at which populations in sub-Saharan Africa are initiating 
ART reflects, among other things, the emergency nature of HIV scale-up in the region,46 
treatment prioritization of the sickest individuals, and absorptive capacity of the health 
care system to meet the overwhelming demand for treatment through scale-up and 
decentralization. However, once past the initial emergency phase, as ART coverage and 
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absorptive capacity reach a steady state equilibrium, an important question is whether 
the late ART problem will persist and whether there are structural interventions at the 
population and clinic-levels that could promote the earlier initiation of ART among 
people with HIV, such that the individual and population-level effectiveness of HIV 
treatment scale-up can be further optimized.
The consequences of late art initiation. A recent randomized control trial from 
Haiti showed a four-fold higher risk among those for whom ART initiation was delayed 
until after CD4 counts dropped below 200 cells/µL compared with those who started 
with CD4 counts between 200–350 cells/µL.35 Late ART initiation translates into sub-
stantial early mortality after the initiation of ART. Low CD4 count and advanced stage 
of disease are the most important predictors of clinical progression and poor survival 
after ART initiation,2,17,27,47–52 and these were a factor in nearly all deaths through 
the first year after ART initiation in one South African study.2 A large review article 
of early mortality following ART initiation by Lawn et al.4 found that 8 to 26% of 
patients initiating ART died within one year, with most dying in the first few months 
after ART initiation often with tuberculosis (TB) related complications.53,54 The range 
in median CD4 counts at ART initiation across the clinics was 43–147 cells/µL.4,53,54 
Another landmark study compared mortality rates in the two years following ART 
initiation among people initiating ART in four sub-Saharan African countries to non-
HIV-related mortality rates in the general population, observing 20–50 times higher 
mortality among patients who initiated with CD4 ,100 cells/µL and WHO stage 4 
than in the general population.5 The authors conclude that much of the excess mortal-
ity could be prevented by timely ART initiation. Finally, another study found that 50% 
of the excess in death rates in the first two years after ART initiation among patients 
treated in Uganda over those treated in London was due to late ART initiation, even 
after accounting for serious opportunistic infections.55 
Patients who initiate ART at low CD4 count remain at risk for opportunistic infections 
for a substantially longer period than patients starting ART at higher CD4 counts,53 
increasing their risk for serious morbidity and death, with TB being the most com-
mon opportunistic illness.8,53 While information on underlying causes of death among 
people on ART is lacking in sub-Saharan Africa, one study found 86% of deaths in 
the first year following ART initiation to be HIV-related (CNS infections, TB, Kaposi’s 
sarcoma, pneumonia, and mitochondrial toxicity), with 7% due to immune reconstitu-
tion syndrome.56
Early mortality in patients who initiate ART is an extension of very high mortal-
ity rates in ART-eligible patients who are enrolled in care but have not initiated ART. 
Importantly, we note that only a handful of studies, all from South Africa, have reported 
on patient outcomes prior to ART initiation,2,11,18,57 all of which found the mortality rates 
to be very high (e.g., 36 deaths per 100 person-years). In fact, deaths among pre-ART 
patients accounted for 66% of deaths (Cape Town)2 and 87% of deaths (Free State)16 
in the entire clinic population. This in turn underscores the need for more research 
on patients at the time of enrollment and in the care phase prior to ART initiation. 
Population-level consequences. Recent clinical trial data (HPTN 052) demonstrated 
that earlier initiation of ART results in near complete interruption of HIV transmission, 
with a 96% reduction in HIV transmission in serodiscordant couples.7 It is estimated 
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that around two to three new infections occur for every one person placed on ART,58 
and it has long been known that late stage HIV infection is associated with higher rates 
of HIV transmission due to elevated viral load levels.59,60 A study with serodiscordant 
couples from a cohort in Rakai, Uganda, estimated that the probability of HIV trans-
mission during late-stage infection increases by four to eight times during the two 
years before death.61,62 Hence, earlier diagnosis, enrollment into HIV care, and more 
timely ART initiation can prevent onward HIV transmission,63–66 both by reducing 
an individual’s infectiousness through ART and by promoting safer sexual behaviors.
Pathways to late art initiation. We have delineated four distinct pathways to 
ART initiation (Figure 1), and key milestones along these pathways: HIV diagnosis 
and enrollment into care. Pathways A, B and C all converge on late ART initiation, but 
through different mechanisms. Pathway D (timely diagnosis → timely enrollment into 
care → timely ART initiation) is the optimal scenario, with ‘timely’ meant to imply 
prior to the onset of advanced stages of HIV disease. While all of these pathways are 
operating to some degree or another in a given clinic or context, they are very differ-
ent with respect to their determinants and therefore the types of interventions to be 
identified and implemented. Further, the relative contribution of each Pathway (A–C) to 
the overall burden of late ART initiation in sub-Saharan Africa is not well understood.
Late diagnosis of HIV/AIDS (Pathway A). Late diagnosis (defined as low CD4 count 
or advanced clinical stage [e.g., AIDS-defining illness]) is an extremely common and 
Figure 1. Pathways to and points of intervention to promote timely Antiretroviral 
Therapy (ART) initiation. 
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persistent problem in both resource-rich33,34,40,67–75 and resource-limited settings.29,38,76–81 
In sub-Saharan Africa, HIV testing uptake is variable, but generally low throughout 
the region; only 4–27% of adults report receiving an HIV test and receiving the results 
in the past 12 months,82 despite the increasing availability of testing opportunities and 
ART. This suggests that late diagnosis is a major contributing factor to late ART initia-
tion in the region. In a study conducted in Nigeria, for example, 50% of HIV-infected 
individuals had CD4 ,200 cells/µL at HIV diagnosis.81 Similarly, in a peri-urban 
community near Cape Town, South Africa, 36% of HIV-infected individuals had 
CD4 ,200 cells/µL and 31% presented HIV-related symptoms (WHO stage 3/4) at the 
time of diagnosis.83 Furthermore, and despite the increase in the annual population 
HIV testing rates in this community from 4% in 2001 to 20% in 2006, the proportion 
that was diagnosed late did not change with time. While many studies in sub-Saharan 
Africa have described CD4 count and stage at ART initiation, the scarcity of data on 
CD4 count and stage at diagnosis makes it difficult to quantify the contribution of 
late diagnosis to the problem of late ART initiation relative to the other pathways in 
Figure 1. However, these data suggest that late diagnosis is a major contributor to late 
ART initiation in the sub-Saharan African region.
Late enrollment in care (Pathway B). Little is known about the factors associated with 
delayed or late enrollment in HIV care among diagnosed HIV-positive people. In a 
study evaluating linkages to care in Cape Town, South Africa, 63% of individuals had 
a CD4 cell count measurement indicative of care linkage within six months of testing 
HIV positive, with those testing at sexually transmitted infection services having the 
highest likelihood (84%) and those testing in VCT services having the lowest likelihood 
(54%) of linkage to HIV care.20 An analysis of a national cross-sectional cohort of Cam-
eroonian HIV-positive adults (ANRS-EVAL study) observed that 30% of participants 
reported delays of three months and 15% waited more than six months before enrolling 
in care.84 A Ugandan study of newly diagnosed HIV-positive adults who enrolled in 
HIV care found that 40% had advanced AIDS-defining disease (WHO Stage 3 or 4).79 
Finally, a recent case-control study in Ethiopia observed that HIV-positive adults who 
lived with their families, lived in a rented house, perceived many ART side effects or 
HIV-related stigma, tested with sickness/symptoms, did not disclose their HIV status 
to their partner, or had frequent alcohol use were more likely to enroll in care late.85 
Late ART initiation despite early enrollment into care (Pathway C). Although late 
ART initiation remains a pervasive problem in sub-Saharan Africa, there are very few 
published data on outcomes following early enrollment into care. Perhaps one of the 
most important reasons why some people may initiate ART late, despite having enrolled 
into HIV care early, is the prioritization of sicker patients for ART initiation, and that 
clinics are often overburdened and lack the absorptive capacity to treat anyone but the 
sickest of the sick.86,87 While this phenomenon may improve with time as the sickest 
patients are treated, as ART coverage increases, and as HIV services are decentralized 
to primary health centers, it may also persist if the sickest patients cannot be treated 
quickly enough.
Despite the limited data available, death prior to ART initiation remains a major 
concern.4,11,88 Poor retention,11,89,90 waiting lists,91,92 lengthy or onerous ART eligibil-
ity procedures,11 lack of integrated TB diagnosis and disease management,93 ARV 
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 stock-outs,39 and inadequate immunologic and clinical monitoring11 have all been 
documented and are potentially important contributing factors to late ART initiation. 
However, the degree to which each of these factors may contribute to the overall burden 
of late ART initiation at the individual or clinic-levels, and the extent to which they 
can be addressed, has not been described.
A large proportion of patients enrolled in HIV care in sub-Saharan Africa (perhaps 
40–50%10,21,94) have not been determined to be ART-eligible and have not yet initiated 
ART; among these individuals, even less is known about the magnitude and determi-
nants of non-retention in care and regular clinical and immunological monitoring to 
help ensure timely ART initiation and OI prophylaxis. A systematic review of pre-ART 
retention in care in Africa suggests that less than one-third of patients testing posi-
tive for HIV and not yet eligible for ART when diagnosed are retained continuously 
in care.95 Among HIV-infected individuals not yet eligible for ART in a rural area of 
South Africa, overall retention was only 45% and younger patients and those at earlier 
stages of the infection had lower odds of being retained, increasing the likelihood that 
these patients will only return for treatment once they develop clinical symptoms, a 
sign of advanced HIV disease.57 The WHO-recommended expansion of ART eligibility 
guidelines in resource-limited settings further highlighted the problem of retention 
because newly eligible patients could not be located.96 Indeed, the fact that most pub-
lished studies on outcomes in HIV care programs have focused primarily on outcomes 
after ART initiation makes it difficult to infer or draw conclusions about outcomes 
prior to ART initiation.42
In summary, for each of the pathways to late ART initiation there are likely structural 
and systemic solutions to some of the problems mentioned above that could increase 
the likelihood of earlier ART initiation among the patient population at many clinics, as 
well as that of future patients in their catchment areas. There is great concern regarding 
the diminishing proportion of people who test HIV positive that are retained along the 
cascade from HIV diagnosis to ART treatment initiation.95 Box 1 summarizes several 
potentially promising strategies that could reduce the problem of late ART initiation at 
different milestones. In the next section, we provide a conceptual framework for and 
review the literature on the determinants of late ART initiation. 
Conceptual framework for determinants of late art initiation. The determinants 
of late ART initiation likely operate at multiple levels. To help delineate these deter-
minants we have developed a conceptual framework for late ART initiation (Figure 2) 
drawing upon the Behavioral Model of Health Services Use,97–99 which has been used 
extensively and adapted to understand the factors that predict use (or non-use) of medi-
cal care services.100,101 Elements of this model include predisposing factors, described 
as pre-existing characteristics of individuals such as age and gender; enabling factors, 
which can include health system factors (e.g., cost of care), as well as individual, 
family and community resources that support or constrain use of care; and need for 
care, described as the individual’s perception of need. The framework includes factors 
measured at the contextual (nationwide or sub-national), clinic, and individual levels, 
which are hypothesized to influence late ART initiation and the relative timing of one 
or more of the upstream milestones on the pathway to late ART initiation—diagnosis 
and enrollment into HIV care.
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Contextual-level factors. Contextual factors include characteristics of the setting and 
population where the HIV epidemic is occurring (e.g., urban/rural, population density, 
socioeconomic status, levels of stigma and HIV knowledge), as well as, indicators of 
HIV burden and health care system capacity (e.g., HIV prevalence, percent of popula-
tion tested for HIV, health care workforce per capita, ART coverage relative to need, 
and national treatment guidelines). 
Characteristics of the setting and general population. HIV-related stigma, routinely 
measured as part of Demographic and Health Surveys (DHS) in sub-Saharan Africa,82 
continues to be pervasive. Anticipated stigma from the community or perceived dis-
crimination in the health care system is likely to inhibit care-seeking,102,103 but only a 
few studies in sub-Saharan Africa have focused on how stigma influences the deci-
sion to seek testing or medical care.39,104 Qualitative studies in Tanzania, Ethiopia, and 
Zambia found that perceived stigma was a barrier to seeking treatment for infections 
closely associated with HIV,105,106 and in Botswana, stigma was associated with ART 
adherence difficulties.107 A qualitative study in Uganda observed that perceived stigma 
and misconceptions about ARVs contributed to delays in ART initiation,39 however, 
whether and to what extent population-level stigma influences HIV-related health-
seeking behaviors among HIV positive people (e.g., testing, enrollment, and ART 
initiation) has not been extensively examined in sub-Saharan Africa. 
The type of community (urban vs. rural) can also be a factor, since differences exist 
in community characteristics in terms of density of population, distance to and avail-
ability of clinics and hospitals and infrastructure within clinics (e.g., availability of 
CD4 testing).22,28 A study by Ingle et al. in South Africa observed that patients in rural 
Figure 2. Multi-level factors associated with late HIV diagnosis, late enrollment into care, 
and late Antiretroviral Therapy (ART) initiation. 
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clinics had lower rates of starting ART treatment and higher mortality than patients 
in urban/peri-urban clinics,18 but more studies evaluating this association in different 
contexts are needed. DHS data,82,108 as a source of contextual information, linked with 
contemporaneous routinely collected HIV program outcome data110 may be particu-
larly useful to this end. For example, one recent study found that higher levels of HIV 
testing coverage and AIDS knowledge were associated with a lower likelihood of late 
ART initiation among populations of people initiating ART.28 
National HIV burden and health care system capacity. The health care worker 
shortage in the sub-Saharan African region is well-documented,109,110and concerns 
about meeting the demands of scale-up have been raised.111 The capacity of the health 
care system to respond to the burden of HIV in a community, district or catchment 
area are also likely to have important influences on the timing at which individuals 
reach each of the key milestones in pathways to ART initiation (Figure 1). In one large 
study, provider to patient ratio was associated with a lower median CD4 count among 
cohorts of patients initiating ART in 8 sub-Saharan African countries.28 In a cohort 
of HIV-infected children in South Africa, insufficient human resources in the clinics 
was noted as the second most common reason for delays in ART initiation.103 Finally, 
national HIV care and treatment guidelines that specify the CD4 count and clinical 
stage at which patients are considered eligible for ART vary somewhat from country 
to country and likely influence the timing of ART initiation among populations of 
individuals enrolled in care. 
Clinic-level factors. Clinic factors including clinic policies and practices, programs 
(e.g., ancillary services), capacity, and pre-ART care effectiveness likely have a direct 
impact on each of the milestones on the pathway to late ART initiation. There may be 
strategies that clinics can adopt to promote timely ART initiation among their existing 
and future patients, some of which could represent effective and scalable intervention 
strategies.28,72
Clinic policies and practices. Clinical policies, such as the number of clinic days and 
clinic hours, have not been examined in detail but substantial variability exists and it 
is possible that limited clinic days and hours could hinder enrollment, retention, and 
appointment adherence for some patients.68,111 Certain record-keeping practices, such 
as keeping appointment books and attendance registers, are associated with improved 
appointment adherence and more timely outreach for patients who miss visits.28,112 
Costs of care attendance. It has been shown that those receiving ART in clinics 
providing it free of charge have significantly lower mortality than patients from clin-
ics where a fee is charged,6 although others have shown that free care is not enough, 
especially for vulnerable populations.113 Cost of transportation to the clinic can also 
pose substantial practical barriers to keeping clinic appointments, especially since it 
is a recurrent cost.114 Furthermore, to avoid being seen by neighbors or recognized by 
clinic staff, some patients may enroll in care at a clinic farther from their home,115,116 
exacerbating the problem of transport. 
Programmatic approaches. Programmatic approaches used by clinics—including 
active testing and the provision of ancillary patient support services such as adherence 
support, peer education, and outreach for patients who miss clinic visits—may have 
direct effects on patient behaviors and are feasible to implement and sustain in sub-
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Saharan Africa, as they are already being widely implemented in sub-Saharan African 
settings.28 Outreach programs have proven to be effective at returning patients who were 
lost to follow-up to care in several studies, and could therefore have a positive effect in 
reducing the proportion initiating ART late.117–120 Cohorts of patients initiating ART 
at clinics that provide care adherence support services targeted at pre-ART patients 
have been shown to be less likely to have low median CD4 count at ART initiation.28 
Clinic capacity and effectiveness of pre-ART clinical care. The type and number of 
staff providing HIV care (e.g., physicians, nurses, clinical officers) and the provider-to-
patient ratio are also potentially important clinic-level factors. For example, in a study 
conducted in South Africa, patients at clinics with a lower staff-to-patient ratios had 
lower rates of starting ART treatment than those with higher staff-to-patient ratios.18 
Another study of cohorts of patients initiating ART in eight sub-Saharan African coun-
tries found lower provider to patient ratio to be associated with a lower median cohort 
CD4 count at ART initiaton.28 Similarly, heavy workloads and long waiting times at the 
clinic could also impact the care received by pre-ART patients and reduce the frequency 
of visits, which would consequently affect the determination of ART eligibility, as well 
as retention in pre-ART care. In fact, waiting times have been reported in several stud-
ies as one of the major challenges that patients face for appointment adherence.114,121,122 
Individual-level factors. Individual factors, beyond clinical parameters, may have a 
major impact on timely ART initiation. We have grouped these into predisposing fac-
tors, enablers/barriers, and perceived need among HIV infected people.
Predisposing factors. Pre-existing characteristics of individuals such as demograph-
ics, socioeconomic status, mental disorders or substance abuse might also affect the 
timing of each milestone along the path to ART initiation. For example, on average, 
women initiate ART at an earlier stage of HIV disease than men.27,123 The reasons likely 
include that women have more regular contact with the health care system and associ-
ated opportunities for HIV testing, especially via antenatal care, or holding different 
health-related beliefs. Additionally, both individual and household socioeconomic status 
may predispose individuals to delay care-seeking or to default from care, most notably 
through the competing demands and opportunity costs of care. In a study conducted in 
Uganda, financial constraints were found to be a reason for delay in ART initiation.124 
Competing work- or home-life demands (such as the inability to take time off from 
work or leave a child or elderly person at home) would likely also play a role in delaying 
care. In a study looking at loss to follow-up among pre-ART patients in South Africa, 
patients who were unemployed were nearly twice as likely to be lost from care before 
ART initiation as those employed.11 Finally, in areas with highly mobile populations, 
relocation was also reported as a reason for non-retention.125
Enablers/barriers. These include parts of an individual’s health-related knowledge/
beliefs, social environment as well as characteristics of the health care system—as 
perceived by or engaged with by the patient—that could support or hinder timely 
care-seeking.
Treatment-related knowledge. Individuals with higher levels of HIV-related “health 
literacy,” or knowledge concerning HIV disease (the importance of CD4 monitoring 
and ART regimens) may be less likely to initiate ART late and this can be influenced 
by clinic level factors such as peer education programs.126
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Health beliefs, norms, and self-efficacy related to care-seeking. As health beliefs have 
been shown to be important predictors of ART adherence,127–129 they may also be 
associated with timely enrollment and retention in care. Given the gender differences 
in late ART initiation that have been observed in sub-Saharan Africa,27,123 and gender 
differences in internalized HIV-related stigma,130 there is a need to enhance our under-
standing of gender-related beliefs around care-seeking for HIV symptoms. 
Characteristics of the social environment. Well documented in the literature is that 
family and social support are associated with better psychological adjustment, medi-
cation adherence, and slower progression to AIDS.131–134 In particular, social network 
members may facilitate behavioral change by transmitting beliefs and motivations 
concerning treatment to the patient.136 Network support may also result in increased 
logistical support and/or an emboldened sense of moral support.136,137 Social support 
may be particularly relevant to timely ART initiation because policies in many sub-
Saharan countries require a patient to have someone who might be called a treatment 
supporter before being initiated on ART. Therefore, individuals with limited networks, 
or those who are unwilling or unable to disclose, may delay enrolling in or may drop 
out of care. Anticipated stigma appears to be a barrier to HIV testing 138–139 and may 
also be a barrier to enrolling in care once tested, and experienced stigma might be 
related to dropping out of care.
Perceived need. An individual’s perception of need is an important determinant of 
their decision to use care. It is likely that people seek testing because they believe they 
may be infected and those who are also symptomatic will be more likely to enroll 
promptly in care. One South African study showed that being referred for testing by 
a provider was associated with a lower likelihood of linking to long-term HIV care 
compared with patients who made their own decision to test.140
Conclusions
In summary, the published literature points squarely to late ART initiation as a major 
contributor to the problem of early mortality and morbidity following ART initiation 
in sub-Saharan Africa, which threatens to substantially limit the effectiveness of HIV 
care and treatment scale-up in the region, including its direct effect on individuals with 
HIV35 and its indirect effect on HIV incidence.7 The considerable variability in late 
ART initiation across clinics and settings8,28 and its persistence over time points to the 
complex and multi-level nature of the problem. While several studies from sub-Saharan 
Africa have documented low median CD4 count at ART initiation, surprisingly little 
is known about the multi-level (i.e., individual, clinic, and contextual) determinants 
of late ART initiation.28 Importantly, very few studies have examined factors relevant 
to important and distinct upstream milestones along the pathway to ART initiation— 
HIV diagnosis and enrollment into HIV care. Although many different strategies to 
reduce late ART initiation are being utilized across sites and settings in sub-Saharan 
Africa, more evidence is needed on their relative effectiveness and cost-effectiveness. 
In particular, more research is needed to identify the structural determinants that may 
be amenable to intervention. Future research should focus on strategies to diagnose, 
engage, retain, and monitor current and future patients, and this will likely only be 
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accomplished through structural interventions at the societal, policy, and clinic-levels. 
Some strategies to consider that could potentially contribute to reducing late ART 
initiation in sub-Saharan Africa are listed in Box 1.
In the U.S.142 and in New York City,143 the epicenter for HIV in the U.S., HIV treat-
ment has been widely available for more than 15 years. Yet, approximately 26% of people 
diagnosed with HIV have concomitant diagnosis of AIDS at the time of HIV diagnosis, 
and delayed access to HIV care after HIV diagnosis is common.144–147 For example, a 
recent study in NYC showed that nearly 20% of newly diagnosed individuals had not 
yet enrolled in HIV care one year later,148 and this figure may be as high as 30%–40% 
Box 1. 
StrateGieS tHat COuLD POteNtiaLLY CONtriBute tO 




Expand provider-initiated counseling and testing
Offer mobile, home-based or work-based services for HIV 
counseling and testing 
Implement partner-testing services as well as active-testing 
approaches
Increase HIV/AIDS knowledge to reduce community stigma 








Optimize and simplify the referral process across services (e.g., 
reduce the number of return visits newly-diagnosed people need to 
make before becoming enrolled in a care and treatment site)
Provide peer supporters to escort and provide emotional support to 
newly-diagnosed individuals through the linkage-to-care process. 
Use SMS or other reminder systems to follow-up individuals who 
test positive but are not known to have not enrolled in HIV care 
within 30 days







Implement point-of-care CD4 testing to allow for faster 
determination of ART eligibility
Increase retention of pre-ART patients by improving support 
services such as peer educator programs, nutritional support, and 
transport assistance
Shorten programmatic delay from CD4 testing to ART initiation 
(e.g., by streamlining clinical and non-clinical aspects of the 
eligibility determination process)
(Continued on p. 374)
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nationwide.70,144,149 Thus, in sub-Saharan Africa, a major concern is that the problem of 
late ART initiation will reach a sub-optimal steady state similar to the United States, 
where, despite substantial investment and near universal availability of HIV-related 
services, an unprecedented number of people living with HIV (including undiagnosed 
HIV150) and several important service and programmatic gaps151 continue to drive HIV 
incidence, and HIV-related morbidity and mortality at the population-level.152,153,154 Given 
that millions of Africans will be initiating ART in the coming decade, the number of 
lives potentially saved, directly and indirectly, by reducing late ART initiation would 
be substantial over the long term.155 Very recent data indicating that Rwanda has the 
second highest mean CD4 count at ART initiation in the world (after the U.S.) are very 
encouraging and provide hope for the entire region.156 However, the threat of decreased 
international commitment to HIV/AIDS in sub-Saharan Africa associated with the 
global financial crisis, combined with persistently low testing coverage, low rates of 
linkage to care after HIV diagnosis, and poor retention in HIV care after enrollment 
and ART initiation all have the potential to perpetuate the problem of late ART initia-
tion, and severely limit the full future potential of HIV scale-up in the region.
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Use a systematic approach to track and detect bottlenecks in the 
HIV care process from HIV diagnosis to treatment and follow-up
Investigate upstream determinants beyond the individual-level. 
Capitalize on significant existing aggregate-level data collected as 
part of routinely service delivery or ministry/donor reporting as 
well as DHS data to generate hypotheses regarding the association 
between promising program and contextual level factors and early 
diagnosis, enrollment into care and ART initiation.
Collect data to examine the influence of promising clinic/program-
level factors that are already being used or will soon be rolled out by 
many clinics (e.g., outreach or point of care CD4 testing) to assess 
their relationship to the outcomes of CD4 at enrollment to care and 
CD4 count at ART initiation at the individual and aggregate levels.
SMS 5 Short Message Service, text message 
DHS 5 Demographic and Health Survey 
HIV 5 Human Immunodeficiency Virus 
ART 5 Antiretroviral Therapy
Box 1. (continued)
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